Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Glucagon is a hormone that signals the liver to release glucose into the bloodstream. It's typically given by injection to counteract severe hypoglycemia in people who have diabetes.

On readmission, in January, 1965, no new physical findings were evident, and it was not known whether the zinc glucagon was inactive or the worsening condition was due to progression of the disease.

Testing their glucagon-packed micelles in lab experiments, the researchers found that they disassembled and released glucagon only in liquid environments that mimicked hypoglycemia in humans and ...

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Clinical data to date on safety and efficacy have been limited to small phase 1 or phase 2 trials.

CHICAGO, March 17, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

Three new competitors are about to launch glucagon, turning this duopoly into a potential 5-player market. Epinephrine revenues should meaningfully disappoint as shortage benefits alleviate, ...

In 2019, semaglutide and liraglutide accounted for 31.4 and 35.3% of all new GLP-1RA prescriptions, while these proportions were 88.1 and 10.3%, respectively, in 2023.

On readmission, in January, 1965, no new physical findings were evident, and it was not known whether the zinc glucagon was inactive or the worsening condition was due to progression of the disease.